Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(16 sites)
South Korea
SCH University Hospital Bucheon, Bucheon-si Chonam National University Hospital, Gwangju Inje University Ilsan Paik Hospital, Ilsan Pusan National University Hospital, Pusan Hallym Sacred Heart Hospital, Pyeongchon Seoul National University Bundang Hospital, Seongnam Asan Medical Center, Seoul Catholic University Seoul St. Mary's Hospital, Seoul Korea University Anam Hospital, Seoul Korea University Anam Hospital, Seoul Samsung Medical Center, Seoul Seoul National University Hospital, Seoul Yonsei University Severance Hospital, Seoul Ajou University Hospital, Suwon Wonju Severance Christian Hospital, Wŏnju